Boehringer Ingelheim has announced the launch of a new set of Marek's disease vaccines in the UK and the EU, named PREVEXXION RN and PREVEXXION RN+HVT+IBD.

The World Organization for Animal Health (OIE) describes Marek's disease as a major economic risk for poultry flocks, particularly those of young adult fowls about to be utilized for meat or egg production. Vaccination against Marek's disease can considerably reduce mortality.

The PREVEXXION RN range is made up of an innovative serotype-1 construct vaccine. According to Boehringer Ingelheim, its early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strains.

It is also fully compatible with VAXXITEK HVT+IBD and is available as a 3-in-1 solution – named PREVEXXION RN+HVT+IBD – specifically designed to provide protection from the hatchery.

Jerôme Baudon, head of poultry at Boehringer Ingelheim, called PREVEXXION RN the “new golden standard” for Marek's disease vaccination programs. He said: “Our PREVEXXION RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection.

“Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.”

PREVEXXION RN vaccines are available in ampoules of 1,000, 2,000, and 4,000 doses, frozen in liquid nitrogen. For more information please contact your Boehringer Ingelheim representative.